Government Intervenes in Pharmaceutical Industry Dispute Over Patent Treaty

Argentina's government is intervening in a dispute within the pharmaceutical industry over the nation's potential adherence to the Patent Cooperation Treaty (PCT). The Chamber of Deputies is currently considering the treaty, which has generated significant opposition from domestic laboratories, grouped under the Argentine Chamber of Pharmaceutical Laboratories (Cilfa).

Cilfa argues that ratifying the PCT would lead to higher drug prices. Conversely, foreign pharmaceutical companies, represented by the Argentine Chamber of Medicinal Specialties (Caeme), endorse the treaty. They contend that it would foster a more predictable environment for innovation-related activities within the country.

The PCT, originally drafted in Washington in 1970, received preliminary approval from Argentina's Senate in 1998. This year, the Congress advanced its consideration as it aligns with commitments made by Argentina in the Reciprocal Trade and Investment Agreement (ARTI) signed with the United States. The treaty aims to integrate Argentina into the primary international system for patent cooperation.

Key provisions of the PCT include extending the timeframe for inventors to protect their inventions from 12 to 30 months, allowing for a single application to be filed in all 158 member states, and incorporating a non-binding international preliminary examination. Cilfa has expressed concerns that these preliminary examinations could influence local decisions and facilitate the approval of patents currently being rejected, potentially extending monopolies through a practice known as "evergreening."

“

The option most convenient for limiting adverse effects on competition, including public health and national industry and employment, while also allowing compliance with the commitment to the United States through adherence to the treaty.